Evidence map›Paper›PMID 40883275›Full record

ArticleBlood cancer journal2025

State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.

Christine E Ryan, Inhye E Ahn, Aswin Sekar, Andrew Rawstron, Julia Almeida, Iñaki Martin-Subero, Erin M Parry, Miguel Alcoceba, Dinis P Calado, Alberto Orfao and 13 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Christine E Ryan *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2588-1943
Inhye E Ahn *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Aswin SekarDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew RawstronLeeds Teaching Hospitals NHS Trust, Leeds, UK.
Julia AlmeidaTranslational and Clinical Research Program, Cancer Research Center (IBMCC; CSIC-University of Salamanca); Cytometry Service (NUCLEUS); Department of Medicine, and ECRIN M3 Consortium, University of Salamanca, Salamanca, Spain.ORCID 0000-0003-3124-8917
Iñaki Martin-SuberoInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0001-8809-5195
Erin M ParryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Miguel AlcocebaInstituto de Investigación Biomédica de Salamanca, and ECRIN M3 Consortium, Salamanca, Spain; and CIBERONC, Institute of Health Carlos III., Madrid, Spain.
Dinis P CaladoThe Francis Crick Institute, London, UK.
Alberto OrfaoTranslational and Clinical Research Program, Cancer Research Center (IBMCC; CSIC-University of Salamanca); Cytometry Service (NUCLEUS); Department of Medicine, and ECRIN M3 Consortium, University of Salamanca, Salamanca, Spain.ORCID 0000-0002-0007-7230
Anton W LangerakDepartment of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands.ORCID 0000-0002-2078-3220
Hendrik VeelkenDepartment of Hematology, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-9108-3125
Petra LangerbeinsDepartment I of Internal Medicine and German CLL Study Group, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Deborah M StephensUniversity of North Carolina Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Sameer A ParikhDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-3221-7314
Carsten U NiemannRigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0001-9880-5242
Sandrine RoullandAix-Marseille University, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.ORCID 0000-0001-8529-640X
Susan L SlagerDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5173-4712
Tait ShanafeltStanford University School of Medicine, Stanford, CA, USA.
Paolo GhiaUniversità Vita-Salute San Raffaele, Milano, Italy.ORCID 0000-0003-3750-7342
Jessica OkosunBarts Cancer Institute, Queen Mary University of London, London, UK.ORCID 0000-0001-6021-5044
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Matthew_Davids@DFCI.Harvard.edu.ORCID 0000-0003-4529-2003

Funding

Optimizing novel agent combination therapy for previously untreated, high risk chronic lymphocytic leukemiaR01CA266298 · NCI · DANA-FARBER CANCER INST · PI MATTHEW S DAVIDS · 2022 to 2026
$2.0M
Tracing the Evolution of Chronic Lymphocytic Leukemia to Richter's Syndrome: Defining TransformationK08CA270085 · NCI · DANA-FARBER CANCER INST · PI Erin M Parry · 2022 to 2026
$945k
NCI NIH HHS K08 CA270085NCI NIH HHS R01 CA266298
6 · The paper itself

Abstract

In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.

Indexed as

B-LymphocytesLeukemia, Lymphocytic, Chronic, B-CellLymphocytosisDisease ManagementDisease ProgressionHumans

Identifiers

PMID40883275
PMCPMC12397339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.